首页|脑立清胶囊联合缬沙坦治疗老年肝阳上亢型高血压患者的效果

脑立清胶囊联合缬沙坦治疗老年肝阳上亢型高血压患者的效果

扫码查看
目的:观察脑立清胶囊联合缬沙坦治疗老年肝阳上亢型高血压患者的效果.方法:选取 2021 年 1 月至 2023 年 8 月该院收治的 80 例老年肝阳上亢型高血压患者进行前瞻性研究,按照随机数表法将其分为对照组与观察组各 40 例.对照组口服缬沙坦治疗,观察组在对照组基础上联合脑立清胶囊治疗.比较两组临床疗效,治疗前后血压(舒张压、收缩压)、心肌重构指标[室间隔厚度(IVST)、左心室后壁厚度(LVPWT)、左心室舒张末期内径(LVEDD)]、血清炎性因子[白细胞介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)、内皮素-1(ET-1)]水平,以及不良反应发生率.结果:观察组治疗总有效率为 95.00%(38/40),高于对照组的 77.50%(31/40),差异有统计学意义(P<0.05);治疗后,观察组舒张压、收缩压、IVST、LVPWT、LVEDD、IL-1β、hs-CRP及ET-1 水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:脑立清胶囊联合缬沙坦治疗老年肝阳上亢型高血压患者可提高治疗总有效率,降低血压、心肌重构指标和炎性因子水平,效果优于单用缬沙坦治疗.
Effects of Naoliqing capsules combined with Valsartan in treatment of elderly patients with hypertension of liver-yang hyperactivity type
Objective:To observe effects of Naoliqing capsules combined with Valsartan in treatment of elderly patients with hypertension of liver-yang hyperactivity type.Methods:A prospective study was conducted on 80 elderly patients with hypertension of liver-yang hyperactivity type admitted to the hospital from January 2021 to August 2023.According to the random number table method,they were divided into control group and observation group,40 cases in each group.The control group was treated with Valsartan orally,while the observation group was treated with Naoliqing capsules on the basis of that of the control group.The clinical efficacy,the levels of blood pressure(diastolic blood pressure,systolic blood pressure),the myocardial remodeling indexes[interventricular septal thickness(IVST),left ventricular posterior wall thickness(LVPWT),left ventricular end-diastolic diameter(LVEDD)],and the serum inflammatory factors[interleukin-1β(IL-1β),high-sensitivity C-reactive protein(hs-CRP),endothelin-1(ET-1)]before and after the treatment,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.00%(38/40),which was higher than 77.50%(31/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of diastolic blood pressure,systolic blood pressure,IVST,LVPWT,LVEDD,IL-1β,hs-CRP and ET-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Naoliqing capsules combined with Valsartan in the treatment of the elderly patients with hypertension of liver-yang hyperactivity type can improve the total effective rate,reduce the levels of blood pressure,myocardial remodeling indexes and inflammatory factors.Moreover,it is superior to simple Valsartan treatment.

ElderlyHypertensionNaoliqing capsulesValsartanLiver-yang hyperactivityMyocardial remodeling

刘甜平

展开 >

吉安市青原区人民医院内科,江西 吉安 343009

老年 高血压 脑立清胶囊 缬沙坦 肝阳上亢 心肌重构

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(18)